Wall Street Analysts Predict a 31.06 percent Upside in Fulgent Genetics Heres What You Should Know
| FLGT Stock | USD 18.95 0.17 0.91% |
Slightly above 51% of Fulgent Genetics' investor base is interested to short. The analysis of overall sentiment of trading Fulgent Genetics stock suggests that many investors are impartial at this time. Fulgent Genetics' investing sentiment can be driven by a variety of factors including economic data, Fulgent Genetics' earnings reports, geopolitical events, and overall market trends.
Fulgent |
The mean of analysts price targets for Fulgent Genetics points to a 31.1 percent upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Read at finance.yahoo.com
 |
Fulgent Genetics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Fulgent Genetics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Fulgent Genetics Maximum Pain Price Across January 17th 2025 Option Contracts
Fulgent Genetics' options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Fulgent Genetics close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Fulgent Genetics' options.
Fulgent Genetics Fundamental Analysis
We analyze Fulgent Genetics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Fulgent Genetics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Fulgent Genetics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Return On Asset
Return On Asset Comparative Analysis
Fulgent Genetics is currently under evaluation in return on asset category among its peers. Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Fulgent Genetics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Fulgent Genetics stock to make a market-neutral strategy. Peer analysis of Fulgent Genetics could also be used in its relative valuation, which is a method of valuing Fulgent Genetics by comparing valuation metrics with similar companies.
Peers
Fulgent Genetics Related Equities
| TTOO | T2 Biosystms | 2.50 | ||||
| TMO | Thermo Fisher | 1.57 | ||||
| GH | Guardant Health | 0.75 | ||||
| A | Agilent Technologies | 0.72 | ||||
| DHR | Danaher | 0.38 | ||||
| ILMN | Illumina | 0.31 | ||||
| MTD | Mettler Toledo | 0.22 | ||||
| CRL | Charles River | 0.12 | ||||
| WAT | Waters | 0.02 | ||||
| NTRA | Natera | 1.08 | ||||
| EXAS | EXACT Sciences | 1.21 | ||||
| CDNA | Caredx | 2.66 | ||||
| TWST | Twist Bioscience | 5.96 |
Additional Tools for Fulgent Stock Analysis
When running Fulgent Genetics' price analysis, check to measure Fulgent Genetics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Fulgent Genetics is operating at the current time. Most of Fulgent Genetics' value examination focuses on studying past and present price action to predict the probability of Fulgent Genetics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Fulgent Genetics' price. Additionally, you may evaluate how the addition of Fulgent Genetics to your portfolios can decrease your overall portfolio volatility.